[January 03, 2014] |
|
Teva Announces Launch of Authorized Generic of Detrol®
JERUSALEM --(Business Wire)--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the
launch of the Authorized Generic of Detrol®* LA (tolterodine
tartrate extended-release capsules) 2 mg and 4 mg in the U.S. market.
Detrol® LA had annual sales of approximately $571.5 million
in the U.S., according to IMS data as of September 30, 2013.
*Detrol® is a registered trademark of Pfizer Enterprises Sarl.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:
This document contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements involve
a number of known and unknown risks and uncertainties that could cause
our future results, performance or achievements to differ significantly
from the results, performance or achievements expressed or implied by
such forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: the ability to
reduce operating epenses to the extent and during the timeframe
intended by our cost restructuring program; our ability to develop and
commercialize additional pharmaceutical products, including our ability
to develop, manufacture, market and sell biopharmaceutical products,
competition for our innovative medicines, especially COPAXONE®
(including competition from innovative orally-administered alternatives,
as well as from potential purported generic equivalents), competition
for our generic products (including from other pharmaceutical companies
and as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our ability to
achieve expected results through our specialty, including innovative,
R&D efforts, the effectiveness of our patents and other protections for
innovative products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions and license
products, uncertainties relating to the replacement of and transition to
a new President & Chief Executive Officer, the effects of increased
leverage as a result of recent acquisitions, the extent to which any
manufacturing or quality control problems damage our reputation for high
quality production and require costly remediation, our potential
exposure to product liability claims to the extent not covered by
insurance, increased government scrutiny in both the U.S. and Europe of
our settlement agreements with brand companies and liabilities arising
from class action litigation and other third-party claims relating to
such agreements, potential liability for sales of generic medicines
prior to a final resolution of outstanding patent litigation, our
exposure to currency fluctuations and restrictions as well as credit
risks, the effects of reforms in healthcare regulation and
pharmaceutical pricing and reimbursement, any failures to comply with
complex Medicare and Medicaid reporting and payment obligations,
governmental investigations into sales and marketing practices,
particularly for our specialty medicines (and our ongoing FCPA
investigations and related matters), uncertainties surrounding the
legislative and regulatory pathways for the registration and approval of
biotechnology-based medicines, adverse effects of political or
economical instability, corruption, major hostilities or acts of
terrorism on our significant worldwide operations, interruptions in our
supply chain or problems with our information technology systems that
adversely affect our complex manufacturing processes, any failure to
retain key personnel or to attract additional executive and managerial
talent, the impact of continuing consolidation of our distributors and
customers, variations in patent laws that may adversely affect our
ability to manufacture our products in the most efficient manner,
potentially significant impairments of intangible assets and goodwill,
potential increases in tax liabilities resulting from challenges to our
intercompany arrangements, the termination or expiration of governmental
programs or tax benefits, environmental risks and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2012 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and the Company undertakes no obligation to update
or revise any forward looking statement, whether as a result of new
information, future events or otherwise.
GST621905-01
[ Back To TMCnet.com's Homepage ]
|